There's been an issue, obviously, with Covid in China.
They are reopening now. They have some level of infection.
But you also have to deal separately with Park Slope.
Where do you stand with tax love? In China right now?
Right now, the authorities that would like to get as much as they can and we
are sending them IBEX globally. We have seen the last one month few
millions of doses that are distributed immediately in all times in time.
And they're making a very big difference.
Is there any move from China go to an RNA vaccine, not the effects of a
treatment, but the vaccine? I don't know.
I think and I have heard that they do have some companies that are doing their
own local tomorrow and a very sense, but they don't have more information about
it. So obviously, you've been enormously
successful. You would be on track in the vaccine.
Thank you. By the way, he's only received it.
Thank you for saying that. What comes next?
Oh, the vaccine facility for Covid. What about variations for some of the
patients we're seeing coming out? Are you developing those and where are
you in that process? Every time there's a variation, we'll
have a standard process that we isolate the virus.
We try to see if the virus, the variant, escapes the protection for a vaccine.
If we have suspicion that it might, we started working like if we are going to
make a vaccine. Many of these various disappear.
So they were not any certain way. But if someone's stopped growing, then
we are not losing time because we have already prepared those steps and make on
one yet to get around. You know, excellent.
Always we find them to discuss the date with authorities, but the ones that will
make this decision is not Pfizer or there nor any manufacturer at these CDC
and the FDA. It is the European authorities.
It is the Israeli authorities. This is the head of the voters are very
confident that will last. We based on the data, we want you to
make this vaccine as a new generation of vaccine.
I mean, I've gotten, I think, two or three first boosters now after the
initial vaccine. It lasts a while.
Are we going to have to get it every year or are you developing something
that might actually last longer? No, it doesn't.
Doesn't last the current wants and it doesn't let the disease.
For example, if you get disease, you can get.
This is again, after three months with the same even variant, not even an
option, it seems, or the very that's why is very difficult for this virus to
eradicate. I don't think it will.
But we are working to see if we can get an annual vaccine.
An nine year old vaccine will be ideal because people will remember they can do
it with other vaccinations like flu and can can last.
OK, flu, you raised it. Where are you in developing?
Because I know. I think that's what you're originally
doing beyond. I.
I'm already for flu. Where are you on a flu vaccine?
They sent MRI on a are the star of this army.
They have completely recruited who are waiting for cases as they accumulate
means that people who have been vaccinated.
Good placebo vaccine and the disease, some of them will get disease.
And then we are waiting to blind the data to see what this government I think
we're coming this year in 2040. That's what I going to ask.
I mean, you can't guarantee a timeline depending on the clinical trial.
No, because that's your best guess. What would you think?
I think by the first half of the year, maybe first half of the year zooms and
like. And so how far are we away from one
vaccine that's both Covid and flu together?
First, we need to have the flu. And if we have a flu already, we start
to do the experiments to combine the two so that we don't lose time again.
I think will come more or less altogether if it is successful.
So you've been very successful with the Covid vaccine and I think has returned a
fair amount to your top line and your bottom line.
But what about the rest of your business?
How are you developing other pharmaceuticals actually come and take
up some of that. Thank you for asking because indeed,
this is the most people year for Pfizer or starting this month and for the next
18 months, we are launching 19 new Bendigo products, 19.
There was never a company in the pharmaceutical company.
And us, of course, that we undertook sets such an operation.
Nineteen different products. Anything to remind you make two months
their cover. Vaccines, 5 2.
New medicines for cancer, 1 for lymphoma, the other for prostate cancer,
2 for metabolic diseases. So it's a very broad range of products
and we are going to be very, very busy vaccinating babies.
As you say, it's critical when we have a sense of how those do.
You know, once you launch a product, typically there's a very high
correlation in the festival months how that will do for the entire year in the
six months. Also very strong correlation.
So you've got another six months. You get the good feeling when things are
moving. So one of the issues with the Covid
vaccine has been some of the developing countries.
Some countries have been left behind, by the way.
It's not limited to pharmaceuticals, not limited Covid.
There's a problem in general about that in the world, but specifically when it
comes to what you're doing. I know you have something called the
accord. Tell us about that.
I will deliver it. But also, just to clarify for the
vaccines, where the vaccine those countries in the world would offer
completely free through a brave move that the government made the U.S.
government, they bought 1 billion doses for months at cost and they offered it
for free to the world. Unfortunately, they were not able to
absorb it because there's not demand for those vaccines and unfortunately the
poorest of the countries. But nevertheless, that gave us
the whole story with Covid sensitization even more so.
Nine months ago here in Davos, we launched in a corner where we said that
Pfizer will offer all of the patent pathetic products, which means the
products that the generic manufacturers cannot make cheap
copies at cost. And they say, of course, these
manufacturers and sent no regulatory, no compliance, no legal nor administrative
notice notices to one point two billion people living in the 45 forest countries
of the world about copying in nine months ago.
And already by the end of the year, it sent sending
products to some of these countries. What we did yesterday was even more
historic move. We announced not all our patent
protected, but all our problems. These moves at least from 20 three
products to over 500 miles. So it's not just the ones patent patent
protected technology, our products. I think also we are hearing whenever a
word it will give, for example, would give them may be the most prescribed
breast cancer medicine. There were high technology, but they
will say also meats or antibiotics will have meats for on the part of city meats
for anesthetics or basic chemotherapy. And
we have them. And then we did everything I might say.
That sounds wonderful. Absolute wonder if you wondered why did
you do it? Because we ought to do it.
I don't think it is. There is no reason why the poorest
countries in the world right now won't have access to the same medicines that
the kids in America or in France are having.
One of the reasons I think Pfizer has been as successful has been because
there's been investment in science. Basically, what about the larger for the
U.S. government and other governments are
reinvesting enough in basic RFD. Could that help you?
I think we would. And I think there is a lot of work
happening, particularly in the U.S. and this is why in the U.S., because I
tracked it all the research investments over the private sector, if you see what
is going on, even companies that there are European
companies are doing most of their research in the U.S.
because this is where things are happening.
I think it is the crown jewel of the U.S.
industry, the life sciences, you know, health care so terribly well.
Dr. Brawley, let me ask you what you think
the biggest challenges in actually having the drugs, the pharmaceuticals to
administer, or is it actually the infrastructure to cure it?
Really? You mentioned earlier that you actually
couldn't get some of the Covid vaccines in countries that needed it.
No, there is no doubt in Africa. It is not the availability of the
products. Of course, you need to have them and you
need to have them the prices that you can pay.
But once you resolve that, which we just did.
You are going to have very big problems with infrastructure.
You don't have the right health care professionals to administer to make the
diagnoses. This is where we should help.
This is where it should help us included.
But also the U.S. government with through U.S.
aid, the other organizations that they aim is to improve health and improve the
health inequities. This is where we should focus our
attention. W8 So
they're doing a fantastic job. W.H.
So this is where we should all partners together.